Aussie Biotech Targeting E. Coli and Campylobacter Infections with New Oral Therapeutic

Australian biotechnology company, Immuron Limited (Nasdaq: IMRN) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in collaboration with the US Naval Medical Research Command (NMRC). The NMRC has prioritized the clinical development of the study to evaluate the efficacy of Immunron’s CampETEC product, a prophylactic therapeutic designed to prevent infectious diarrhea caused by Campylobacter.

The study’s first participants have been enrolled in the in-patient portion of the study which is anticipated to be completed by the end of December 2023.

Highlights

The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, MD.

The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product compared to a placebo in a controlled human infection model (CHIM). The primary efficacy outcome is prevention and/or reduction of moderate to severe diarrhea.

The estimated study completion date is June 2024 with topline results from the clinical trial expected in 2H 2024.

Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity and associated discomfort stemming from diarrhea decreases daily performance, affects judgment, decreases morale and declines operational readiness. A preventative treatment that defends against infectious enteric diseases is a high priority objective for the US Military. 

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. For more information visit: http://www.immuron.com